Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mephtazolol
- Development stage
- Phase 2
- Lead developer
- Shandong Taitian New Drug Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mephtazolol is a novel small molecule analgesic developed by Shandong Taitian New Drug Development for the management of moderate to severe pain, specifically postoperative pain. Chemically, it is a derivative of meptazinol and is classified as a Class 1.1 new drug in China. Mephtazolol primarily functions as an opioid receptor agonist, likely targeting the mu-opioid receptor to provide analgesic effects. Clinical development has focused on its use as an oral tablet for short-term treatment of moderate pain following orthopedic surgery, where it has been evaluated in Phase II trials (e.g., CTR20150566) against active comparators such as tramadol.
- Other names
- mephtazolol hydrochloride美他唑醇
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on mephtazolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mephtazolol.